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Conclusions: Routine screening is not warranted as
no hVISA isolates were detected. Some strains had a
Macro E-test MIC of 6.0g/ml for both glycopeptides.
This suggests that periodic screening of S. aureus isolates
from BSI may be useful to check for the occurrence of
hVISA.
doi:10.1016/j.ijid.2008.05.717
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Objectives: S. pneumoniae (SPN) continues to be recog-
nized as a signiﬁcant respiratory and bacteremic pathogen.
Resistance to both oral and parenteral antibiotics used to
treat SPN infection is evolving and newer antibiotics are
needed with anti-SPN activity. This report documents the
activity of tigecycline and comparators against 5501 SPN
collected globally since 2004.
Methods: Between 2004—2007, 387 hospital sites in 48
countries collected 5501 SPN deemed clinically signiﬁcant
from a variety of sources. MICs were determined at each
site using supplied brothmicrodilution panels and MIC results
interpreted by CLSI standards at each site.
Results: The % SPN inhibited at each MIC are shown
below:
Conclusions: Tigecycline demonstrated excellent in vitro
activity against SPN with 100% of isolates inhibited at
≤0.5mcg/ml. Globally, only 61.5% of SPN were suscepti-
ble to penicillin, while 0.2% were resistant to levoﬂoxacin.
Continued surveillance of resistance in SPN to new and
established antimicrobials is warranted.
doi:10.1016/j.ijid.2008.05.718
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Objectives: Tigecycline, a new glycylcycline is an ana-
logue of tetracycline that demonstrates activity against
bacterial strains carrying tetracycline (minocycline) resis-
tance mechanisms. This report documents the activity of TIG
against minocycline resistant isolates collected worldwide,
2004—2007, as part of the Tigecycline Evaluation Surveil-
lance Trial (TEST) study.
Methods: Between 2004 and 2007, 387 hospital sites in
48 countries collected signiﬁcant pathogens associated with
8 specimen types, were identiﬁed to species level and MICs
performed for each strain to a supplied panel of antibiotics
and interpreted according to CLSI guidelines.
Results: The table below illustrates the activity of tige-
cycline to minocycline resistant pathogens.
Conclusions: Tigecycline MIC90s were ≤0.5mcg/ml for
minocycline resistant gram-positive pathogens such as Ente-
rococcus and S. aureus (including MRSA) and ≤8mcg/ml
for minocycline resistant gram-negative pathogens such
as Enterobacteriaceae, including ESBL producers. Tigecy-
cline demonstrated minimal activity against P. aeruginosa.
Tigecycline demonstrates enhanced activity to many
minocycline resistant pathogens.
doi:10.1016/j.ijid.2008.05.719
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Background: Worldwide S. aureus are increasingly dis-
playing resistance to multiple drug classes. Therapeutic
options to multi-drug resistant (MDR) S. aureus phenotypes
are limited. Tigecycline, a new glycylcycline offers the
potential of enhanced activity against MDR S. aureus. The
tigecycline evaluation surveillance trial (T.E.S.T.) evaluated
the activity of tigecycline and comparators to MDR S. aureus
isolated worldwide.
Methods: 335 hospital sites in 47 countries between 2004
and 2007 collected 7,557 clinically signiﬁcant S. aureus.
MICs were determined using broth microdilution panels and
results interpreted as speciﬁed by CLSI at each site. S.
aureus strains were categorized into groups according to the
number of drug classes to which they were resistant (MDR
groups 0 to 4).
Results: MIC90 of tigecycline and comparators for MDR
groups 0 to 4 are shown in the table.
Conclusions: Tigecycline in comparison to 10 relevant
comparators exhibited the lowest MIC90 against S. aureus
isolated worldwide irrespective of MDR phenotype and mul-
tiple drug class resistance.
doi:10.1016/j.ijid.2008.05.720
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Background: Daptomycin is a cyclic lipopeptide with
potent bactericidal activity against Gram-positive organ-
isms. Daptomycin has been used in the USA and Europe for
the treatment of complicated skin and soft tissue (cSSTI)
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and bloodstream infections (BSI) for several years. We eval-
uated the in vitro activity of daptomycin and comparators
against recent (2006) clinical isolates collected in 5 Asia-
Paciﬁc (APAC) countries.
Methods: 523 consecutive strains were collected in (no.
of strains; medical centers) Hong Kong (100; 1), Indone-
sia (63; 3), Philippines (124; 2), Singapore (119; 1) and
Thailand (117; 2). Most isolates were from cSSTI and BSI.
Organisms evaluated included: S. aureus (SA; 326 strains);
coagulase-negative staphylococci (CoNS; 31), enterococci
(92), viridans group streptococci (VGS; 32) and -haemolytic
streptococci (BHS; 42). Antimicrobial susceptibility was
evaluated by reference broth microdilution methods in
cation-adjusted Mueller-Hinton broth with 50mg/L of cal-
cium for daptomycin tests.
Results: Daptomycin was highly active against SA (100.0%
susceptibility) with minor variations among countries.
Among SA, oxacillin resistance varied from 29.6% in Thailand
to 80.4% in Singapore; while the highest rates of resis-
tance to clindamycin and trimethoprim/sulfamethoxazole
were observed in Indonesia (46.9 and 59.6% respectively),
Thailand (28.3 and 39.1%) and Singapore (29.6 and 31.5%).
Daptomycin inhibited all CoNS strains at ≤1mg/L or less
and was two- to four-fold more potent than vancomycin or
linezolid against SA and CoNS. Enterococci were also very
susceptible to daptomycin (MIC50/90, 1/4mg/L; 100.0% sus-
ceptible) and vancomycin resistance was observed only in
Thailand (2.0%, VRE). VGS and BHS strains showed lower dap-
tomycin MIC values (MIC90, 1 and 0.25mg/L respectively).
Conclusions: Antimicrobial susceptibility patterns of
Gram-positive organisms varied substantially among the
APAC nations evaluated and daptomycin exhibited complete
coverage (100.0% susceptibility) and high potency against a
large collection of contemporary clinical strains collected in
9 hospitals from 5 APAC countries.
doi:10.1016/j.ijid.2008.05.721
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Background: Daptomycin, a novel cyclic lipopeptide,
exhibits a unique mechanism of action that includes binding
to, and depolarizing, the bacterial membrane resulting in
rapid loss of cellular function and cell death. We evaluated
the in vitro activity of daptomycin against recent clinical
isolates collected in ten Chinese hospitals.
Methods: 924 consecutive strains were collected in Chi-
nese medical centers in 2006. The organisms, one per
patient, were isolated mainly from bloodstream and skin
and soft tissue infections. The following pathogens were
evaluated: S. aureus (SA; 37.5% oxacillin-resistant [MRSA]);
coagulase-negative staphylococci (CoNS; 88.9% oxacillin-
resistant), Enterococcus spp. (0.5% vancomycin-resistant
[VRE]) and viridans group streptococci (VGS; 43.8 penicillin-
susceptible). The strains were susceptibility tested by broth
microdilution methods in cation-adjusted Mueller-Hinton
broth supplemented to 50mg/L of calcium for daptomycin
tests. Numerous comparator agents were tested.
Results: All organisms tested were considered suscepti-
ble to daptomycin. Daptomycin was highly active against
SA (MIC90, 0.5mg/L) and CoNS (MIC90, 1mg/L), and two- to
four-fold more potent than vancomycin or linezolid against
these organisms. MRSA showed high rates of resistance to
clindamycin (92.4%), levoﬂoxacin (96.2%) and gentamicin
(95.5%), and daptomycin MIC values slightly higher com-
pared to oxacillin-susceptible SA. All enterococcal strains
were inhibited at the daptomycin susceptible breakpoint of
≤4mg/L, including a few VRE strains. E. faecalis (MIC90,
2mg/L) exhibited daptomycin MIC values lower than E.
faecium (MIC90, 4mg/L). Quinupristin/dalfopristin showed
limited activity (61.7% susceptibility) against E. faecium;
and E. faecalis showed high rate of high-level resistance
to gentamicin (49.8%) and streptomycin (51.7). Daptomycin
was very active against VGS (MIC90, 0.5mg/L).
Conclusions: Daptomycin showed signiﬁcant potency and
broad-spectrum activity against recent clinical isolates
of Gram-positive organisms isolated in Chinese medical
centers, including multidrug-resistant subsets. All Gram-
positive organisms tested were susceptible to daptomycin.
doi:10.1016/j.ijid.2008.05.722
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Objectives: Worldwide methicillin-resistant S.aureus
(MRSA) are increasing dramatically with corresponding resis-
tance to multiple drug classes (MDR). Tigecycline, a new
glycylcycline offers the potential of enhanced activity
against MDR S. aureus. The tigecycline evaluation surveil-
lance trial (T.E.S.T.) evaluated the activity of tigecycline
and comparators to MDR S. aureus(including MR+MS strains)
isolated in the United States.
Methods: 193 hospital sites in the United States, between
2004 and 2007, collected 5280 clinically signiﬁcant S.
aureus. MICs were performed as speciﬁed by CLSI at each
site.
Results: MIC90 of tigecycline and comparators to S. aureus
resistant groups 0—3+ are shown in the following table:
Conclusions: Tigecycline demonstrated in vitro activity
comparable to that of linezolid and vancomycin against all
multidrug resistant groups of S. aureus. Tigecycline in vitro
activity is unaffected by multidrug resistant phenotypes of
S. aureus and offers an alternative in the treatment of infec-
tions due to S. aureus where approved indications apply.
doi:10.1016/j.ijid.2008.05.723
